These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28679777)

  • 1. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 2. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
    Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
    Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
    Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
    Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
    Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
    Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
    Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
    Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.
    Di K; Keir ST; Alexandru-Abrams D; Gong X; Nguyen H; Friedman HS; Bota DA
    J Neurooncol; 2014 Dec; 120(3):473-81. PubMed ID: 25115740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
    Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
    Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
    Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
    Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
    Fukai J; Koizumi F; Nakao N
    PLoS One; 2014; 9(8):e104538. PubMed ID: 25111384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H; Nerio E; Holland EC
    Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.